Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 5 (2008), Issue 2 (February)

1. Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian cancer: a randomised controlled trial.
   Lancet Oncol, 9(2): 124-31. [Abstract] [Full-text]
2. Multiple alternative splicing markers for ovarian cancer.
   Cancer Res, 68(3): 657-63. [Abstract] [Full-text]
3. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis.
   Int J Cancer, 122(7): 1598-603. [Abstract] [Full-text]
4. Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance?
   Gynecol Oncol, 108(2): 428-32. [Abstract] [Full-text]
5. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer.
   Gynecol Oncol, 108(2): 271-5. [Abstract] [Full-text]
6. Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary.
   Gynecol Oncol, 108(2): 370-6. [Abstract] [Full-text]
7. Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner.
   Gynecol Oncol, 108(2): 361-9. [Abstract] [Full-text]
8. Expression and activity of taxane-metabolizing enzymes in ovarian tumors.
   Gynecol Oncol, 108(2): 355-60. [Abstract] [Full-text]
9. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
   Gynecol Oncol, 108(2): 276-81. [Abstract] [Full-text]
10. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
    Gynecol Oncol, 108(2): 402-8. [Abstract] [Full-text]
11. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study.
    Gynecol Oncol, 108(2): 265-70. [Abstract] [Full-text]
12. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
    Gynecol Oncol, 108(2): 415-20. [Abstract] [Full-text]
13. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer.
    Gynecol Oncol, 108(2): 385-94. [Abstract] [Full-text]
14. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
    Gynecol Oncol, 108(2): 421-7. [Abstract] [Full-text]
15. E-cadherin gene polymorphisms and haplotype associated with the occurrence of epithelial ovarian cancer in Chinese.
    Gynecol Oncol, 108(2): 409-14. [Abstract] [Full-text]
16. A patient with bilateral immature ovarian teratoma presenting with paraneoplastic encephalitis.
    Gynecol Oncol, 108(2): 445-8. [Abstract] [Full-text]
17. A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian and primary peritoneal cancers.
    Gynecol Oncol, 108(2): 282-6. [Abstract] [Full-text]
18. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients.
    Gynecol Oncol, 108(2): 336-41. [Abstract] [Full-text]
19. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
    Gynecol Oncol, 108(2): 433-7. [Abstract] [Full-text]
20. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Gynecol Oncol, 108(2): 287-92. [Abstract] [Full-text]
21. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach.
    Gynecol Oncol, 108(2): 348-54. [Abstract] [Full-text]
22. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
    Gynecol Oncol, 108(2): 342-7. [Abstract] [Full-text]
23. The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression.
    Differentiation, 76(2): 193-205. [Abstract] [Full-text]
24. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
    Cancer Invest, 26(2): 185-92. [Abstract] [Full-text]
25. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal.
    Neurology, 70(7): 504-11. [Abstract] [Full-text]
26. Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review.
    Br J Radiol, 81(963): 172-9. [Abstract] [Full-text]
27. Targeting signaling pathways in ovarian cancer.
    Expert Opin Ther Targets, 12(3): 353-65. [Abstract] [Full-text]
28. Predictors and outcomes of recurrent disease after a negative second look laparotomy.
    J Surg Oncol, 97(3): 226-30. [Abstract] [Full-text]
29. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
    J Clin Oncol, 26(6): 890-6. [Abstract] [Full-text]
30. Early events in the pathogenesis of epithelial ovarian cancer.
    J Clin Oncol, 26(6): 995-1005. [Abstract] [Full-text]
31. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis.
    J Neurol Neurosurg Psychiatry, 79(3): 324-6. [Abstract] [Full-text]
32. The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium.
    Cancer Res, 68(4): 1110-8. [Abstract] [Full-text]
33. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer.
    Cancer Res, 68(4): 1100-9. [Abstract] [Full-text]
34. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
    Cancer Res, 68(4): 998-1002. [Abstract] [Full-text]
35. Giant mature ovarian cystic teratoma including more than 300 teeth.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 105(3): e76-9. [Abstract] [Full-text]
36. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
    Oncogene, 27(9): 1273-80. [Abstract] [Full-text]
37. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.
    Lancet, 371(9609): 303-14. [Abstract] [Full-text]
38. Folate receptor alpha as a tumor target in epithelial ovarian cancer.
    Gynecol Oncol, 108(3): 619-26. [Abstract] [Full-text]
39. Hormone replacement therapy and ovarian cancer risk: a meta-analysis.
    Gynecol Oncol, 108(3): 641-51. [Abstract] [Full-text]
40. Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells.
    Gynecol Oncol, 108(3): 632-40. [Abstract] [Full-text]
41. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.
    Gynecol Oncol, 108(3): 493-9. [Abstract] [Full-text]
42. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
    Gynecol Oncol, 108(3): 500-4. [Abstract] [Full-text]
43. Gamma-knife radiosurgery as an optimal treatment modality for brain metastases from epithelial ovarian cancer.
    Gynecol Oncol, 108(3): 505-9. [Abstract] [Full-text]
44. Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas.
    Gynecol Oncol, 108(3): 603-8. [Abstract] [Full-text]
45. The prognostic significance of elongation factor eEF1A2 in ovarian cancer.
    Gynecol Oncol, 108(3): 561-8. [Abstract] [Full-text]
46. Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases.
    Gynecol Oncol, 108(3): 515-9. [Abstract] [Full-text]
47. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
    Gynecol Oncol, 108(3): 510-4. [Abstract] [Full-text]
48. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007.
    Gynecol Oncol, 108(3): 652-7. [Abstract] [Full-text]
49. A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma.
    Gynecol Oncol, 108(3): 627-31. [Abstract] [Full-text]
50. Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer.
    Int J Cancer, 122(8): 1716-21. [Abstract] [Full-text]
51. p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4.
    Int J Cancer, 122(8): 1730-7. [Abstract] [Full-text]
52. Migration deficit in monocyte-macrophages in human ovarian cancer.
    Cancer Immunol Immunother, 57(5): 635-45. [Abstract] [Full-text]
53. Ovarian torsion caused by teratoma masquerading as renal colic.
    Emerg Med J, 25(3): 182. [Abstract] [Full-text]
54. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling.
    Eur J Endocrinol, 158(3): 431-7. [Abstract] [Full-text]
55. DeltaNp63 expression is associated with poor survival in ovarian cancer.
    Ann Oncol, 19(3): 501-7. [Abstract] [Full-text]
56. Hepatic resection for recurrent metastatic ovarian cancer.
    Am J Surg, 195(3): 370-3; discussion 373. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.